Pancreatic cancer – the past, the present, and the future

References

• Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425.
   PubMed Web of Science ®Google Scholar
• Ansari D, Althini C, Ohlsson H, et al. Early-onset pancreatic cancer: a population-based study using the SEER registry. Langenbecks Arch Surg. 2019;404(5):565–571.
   PubMed Web of Science ®Google Scholar
• Pancreatic Cancer Across Europe: Taking a united stand 2018. Published by United European Gastroenterology.
   Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Ansari D, Andersson R. Pancreatic ductal adenocarcinoma: is a cure possible? Future Oncol. 2017;13(10):863–865.
   PubMed Web of Science ®Google Scholar
• Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: surgery is not enough. WJG. 2015;21(11):3157–3165.
   PubMed Web of Science ®Google Scholar
• Kommalapati A, Tella SH, Goyal G, et al. Contemporary management of localized resectable pancreatic cancer. Cancers. 2018;10(1):24.
   PubMed Web of Science ®Google Scholar
• GLOBOCAN 2020. https://gco.iarc.fr.
   Google Scholar
• Tingstedt B, Andersson E, Flink A, et al. Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach. World J Surg. 2011;35(10):2298–2305.
   PubMed Web of Science ®Google Scholar
• Draus T, Ansari D, Wikstrom F, et al. Projected economic burden of pancreatic cancer in Sweden in 2030. Acta Oncol. 2021;60(7):866–871.
   PubMed Web of Science ®Google Scholar
• Pappalardo A, Giunta EF, Tirino G, et al. Adjuvant treatment in pancreatic cancer: shaping the future of the curative setting. Front Oncol. 2021;11:695627.
   PubMed Web of Science ®Google Scholar
• Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2(12):897–909.
   PubMed Web of Science ®Google Scholar
• Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–1117.
   PubMed Web of Science ®Google Scholar
• Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538(7625):378–382.
   PubMed Web of Science ®Google Scholar
• Ansari D, Bauden M, Bergstrom S, et al. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Br J Surg. 2017;104(5):600–607.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA A Cancer J Clinicians. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Danielsson K, Ansari D, Andersson R. Personalizing pancreatic cancer medicine: what are the challenges? Per Med. 2013;10(1):45–59.
   PubMed Web of Science ®Google Scholar
• Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504–511.
   PubMed Web of Science ®Google Scholar
• Jacobson S, Dahlqvist P, Johansson M, et al. Hyperglycemia as a risk factor in pancreatic cancer: a nested case-control study using prediagnostic blood glucose levels. Pancreatology. 2021;21(6):1112–1118.
   Web of Science ®Google Scholar
• Greer JB, Whitcomb DC, Brand RE. Genetic predisposition to pancreatic cancer: a brief review. Am J Gastroenterol. 2007;102(11):2564–2569.
   PubMed Web of Science ®Google Scholar
• Gupta S, Vittinghoff E, Bertenthal D, et al. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol. 2006;4(11):1366–1372.
   PubMed Web of Science ®Google Scholar
• Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212(4490):53–55.
   PubMed Web of Science ®Google Scholar
• Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957–971.
   PubMedGoogle Scholar
• Scara S, Bottoni P, Scatena R. CA 19-9: Biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247–260.
   PubMed Web of Science ®Google Scholar
• Ahola R, Siiki A, Vasama K, et al. Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma. Br J Surg. 2017;104(11):1532–1538.
   PubMed Web of Science ®Google Scholar
• Delitto D, Black BS, Cunningham HB, et al. Standardization of surgical care in a high-volume center improves survival in resected pancreatic head cancer. Am J Surg. 2016;212(2):195–201 e1.
   PubMed Web of Science ®Google Scholar
• Seppanen H, Juuti A, Mustonen H, et al. The results of pancreatic resections and long-term survival for pancreatic ductal adenocarcinoma: a single-institution experience. Scand J Surg. 2017;106(1):54–61.
   PubMed Web of Science ®Google Scholar
• Ansari D, Williamsson C, Tingstedt B, et al. Pancreaticoduodenectomy–the transition from a low- to a high-volume center. Scand J Gastroenterol. 2014;49(4):481–484.
   PubMed Web of Science ®Google Scholar
• Yoshioka R, Yasunaga H, Hasegawa K, et al. Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy. Br J Surg. 2014;101(5):523–529.
   PubMed Web of Science ®Google Scholar
• Williamsson C, Karlsson N, Sturesson C, et al. Impact of a fast-track surgery programme for pancreaticoduodenectomy. Br J Surg. 2015;102(9):1133–1141.
   PubMed Web of Science ®Google Scholar
• Williamsson C, Ansari D, Andersson R, et al. Postoperative pancreatic fistula-impact on outcome, hospital cost and effects of centralization. HPB. 2017;19(5):436–442.
   PubMed Web of Science ®Google Scholar
• Nickel F, Haney CM, Kowalewski KF, et al. Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2020;271(1):54–66.
   PubMed Web of Science ®Google Scholar
• Mazzola M, Giani A, Crippa J, et al. Totally laparoscopic versus open pancreaticoduodenectomy: a propensity score matching analysis of short-term outcomes. Eur J Surg Oncol. 2021;47(3):674–680.
   PubMed Web of Science ®Google Scholar
• Shi Y, Jin J, Qiu W, et al. Short-term outcomes after robot-assisted vs open pancreaticoduodenectomy after the learning curve. JAMA Surg. 2020;155(5):389–394.
   PubMed Web of Science ®Google Scholar
• Akerberg D, Ansari D, Andersson R. Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol. 2016;22(28):6424–6433.
   PubMed Web of Science ®Google Scholar
• Schmocker RK, Delitto D, Wright MJ, et al. Impact of margin status on survival in patients with pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy. J Am Coll Surg. 2021;232(4):405–413.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806.
   PubMed Web of Science ®Google Scholar
• Kaka S, Pawlic TM, PJ A, et al. Exocrine pancreas. Pancreatic adenocarcinoma. In: Amin MB, editor. AJCC cancer staging manual. 8th ed. New York: Springer-Verlag; 2016.
   Google Scholar
• Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15(1):165–174.
   PubMed Web of Science ®Google Scholar
• Hunt GC, Faigel DO. Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc. 2002;55(2):232–237.
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020.
   PubMed Web of Science ®Google Scholar
• Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159(1):358–362.
   PubMed Web of Science ®Google Scholar
• Evans DB, George B, Tsai S. Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 2015;22(11):3409–3413.
   PubMed Web of Science ®Google Scholar
• Tempero MA. New year, new look!. J Natl Compr Canc Netw. 2019;17(1):1–605.
   PubMed Web of Science ®Google Scholar
• Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.
   PubMed Web of Science ®Google Scholar
• Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–347.
   PubMed Web of Science ®Google Scholar
• Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–627.
   PubMed Web of Science ®Google Scholar
• Nurmi A, Mustonen H, Parviainen H, et al. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. Acta Oncol. 2018;57(6):799–806.
   PubMed Web of Science ®Google Scholar
• Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014;20(31):10740–10751.
   PubMed Web of Science ®Google Scholar
• Michelakos T, Pergolini I, Castillo CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733–740.
   PubMed Web of Science ®Google Scholar
• Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457–463.
   PubMed Web of Science ®Google Scholar
• Nurmi A, Mustonen H, Stenman U, et al. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma. Sci Rep. 2021;11(1):781.
   PubMed Web of Science ®Google Scholar
• Nurmi AM, Mustonen H, Haglund C, et al. Changes in CRP and CA19-9 during preoperative oncological therapy predict postoperative survival in pancreatic ductal adenocarcinoma. Oncology. 2021;99(11):686–698.
   PubMed Web of Science ®Google Scholar
• Blair AB, Sorber R, Rozich NS, et al. A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma. Pancreas. 2019;48(8):973–984.
   PubMed Web of Science ®Google Scholar
• Labori KJ, Lassen K, Hoem D, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (norwegian pancreatic cancer trial – 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. BMC Surg. 2017;17(1):94.
   PubMed Web of Science ®Google Scholar
• Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932–942.
   PubMed Web of Science ®Google Scholar
• Eijck CHJV, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: long-term results of the multicenter randomized phase III PREOPANC trial. J Clin Oncol. 2021;39(15_suppl):4016–4016.
   Web of Science ®Google Scholar
• Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–423.
   PubMed Web of Science ®Google Scholar
• Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (prep-02/JSAP05). Jpn J Clin Oncol. 2019;49(2):190–194.
   PubMed Web of Science ®Google Scholar
• Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (prep-02/JSAP-05). J Clin Oncol. 2019;37(4_suppl):189–189.
   Web of Science ®Google Scholar
• Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936–945.
   PubMed Web of Science ®Google Scholar
• Labori KJ, Katz MH, Tzeng CW, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – a population-based cohort study. Acta Oncol. 2016;55(3):265–277.
   PubMed Web of Science ®Google Scholar
• Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117(10):2044–2049.
   PubMed Web of Science ®Google Scholar
• Court CM, Ankeny JS, Sho S, et al. Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer. Ann Surg Oncol. 2018;25(4):1000–1008.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–1585.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147–156.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–1081.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–1481.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Reni M, Riess H, et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol. 2019;37(15_suppl):4000–4000.
   Web of Science ®Google Scholar
• Kharat AA, Nelson R, Au T, et al. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials. J Manag Care Spec Pharm. 2021;27(10):1367–1375.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–348.
   PubMed Web of Science ®Google Scholar
• Jin L, Shi N, Ruan S, et al. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Radiat Oncol. 2020;15(1):76.
   PubMed Web of Science ®Google Scholar
• Harrison JM, Wo JY, Ferrone CR, et al. Intraoperative Radiation Therapy (IORT) for borderline resectable and locally advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the era of modern neoadjuvant treatment: short-term and long-term outcomes. Ann Surg Oncol. 2020;27(5):1400–1406.
   PubMed Web of Science ®Google Scholar
• Buwenge M, Macchia G, Arcelli A, et al. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief. JPR. 2018;ume 11:2169–2178.
   Web of Science ®Google Scholar
• Ansari D, Tingstedt B, Andersson R. Pancreatic cancer – cost for overtreatment with gemcitabine. Acta Oncol. 2013;52(6):1146–1151.
   PubMed Web of Science ®Google Scholar
• Dreyer SB, Chang DK, Bailey P, et al. Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clin Cancer Res. 2017;23(7):1638–1646.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–503.
   PubMed Web of Science ®Google Scholar
• Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–1178.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.
   PubMed Web of Science ®Google Scholar
• Johansson H, Andersson R, Bauden M, et al. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol. 2016;22(43):9457–9476.
   PubMed Web of Science ®Google Scholar
• Andersson R, Pereira CF, Bauden M, et al. Is immunotherapy the holy grail for pancreatic cancer? Immunotherapy. 2019;11(17):1435–1438.
   PubMed Web of Science ®Google Scholar
• Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437–1447.
   PubMed Web of Science ®Google Scholar